



(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(43) Date of publication:
06.10.2021 Bulletin 2021/40

(21) Application number: **19891569.6**

(22) Date of filing: **29.11.2019**

(51) Int Cl.:
A61K 9/08 (2006.01) A61K 47/26 (2006.01)
A61K 47/18 (2017.01) A61K 47/20 (2006.01)
A61K 47/64 (2017.01) A61K 38/48 (2006.01)

(86) International application number:
PCT/KR2019/016669

(87) International publication number:
WO 2020/111852 (04.06.2020 Gazette 2020/23)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **30.11.2018 KR 20180151983**
20.08.2019 KR 20190101723

(71) Applicant: **Huons Biopharma Co., Ltd.**
Seongnam-si, Gyeonggi-do 13201 (KR)


(72) Inventors:
• **KIM, Wanseop Paul**
Yongin-si, Gyeonggi-do 16822 (KR)
• **KIM, Yeong-Mok**
Seoul 04732 (KR)
• **PARK, Gi-Sik**
Suwon-si, Gyeonggi-do 16697 (KR)
• **PARK, Jae-Min**
Suwon-si, Gyeonggi-do 16281 (KR)
• **LEE, Ae-Yeon**
Ansan-si, Gyeonggi-do 15589 (KR)

(74) Representative: **Dehns**
St. Bride's House
10 Salisbury Square
London EC4Y 8JD (GB)

(54) **BOTULINUM TOXIN-STABILIZING LIQUID COMPOSITION**

(57) The present invention relates to a botulinum toxin-stabilizing liquid composition having the effect of improving the stability of botulinum toxin, a method for preparing same, and a pharmaceutical composition containing the stabilizing liquid composition and having improved stability of botulinum toxin. According to the present invention, since the activity of liquid botulinum toxin is maintained for a long time even at room temperature, there are advantages of excellent storage stability and conservation stability and easy administration.

FIG.2



Description

[Technical Field]

[0001] The present invention relates to a stabilizing liquid composition having an effect of improving the stability of botulinum toxin, a method of preparing the same, and a pharmaceutical composition for improving the stability of botulinum toxin, which includes the stabilizing liquid composition.

[0002] The application claims priority to and the benefit of Korean Patent Application No. 10-2018-0151983, filed on November 30, 2018, and Korean Patent Application No. 10-2019-0101723, filed on August 20, 2019, the disclosures of which are incorporated herein by reference in their entireties.

[Background Art]

[0003] There are 127 species or more classified by morphology and function in the genus *Clostridium*. Anaerobic, gram-positive bacteria, *Clostridium botulinum*, generates a potent polypeptide neurotoxin, such as botulinum toxin (hereinafter, the "toxin" used herein is also used interchangeably), causing a neuromuscular disease known as botulism in humans and animals. Symptoms of the botulinum toxin poisoning may include gait abnormalities, dysphagia, speech disorders, and paralysis of respiratory muscles which may lead to death.

[0004] One unit of the botulinum toxin is defined as LD₅₀ when intraperitoneally injected into female Swiss Webster mice weighing approximately 18 to 20 g. One unit of the botulinum toxin is the amount of botulinum toxin that kills 50% of a group of female Swiss Webster mouse.

[0005] The characteristics of seven types of immunologically distinct botulinum neurotoxins, such as botulinum neurotoxin serotypes A, B, C, D, E, F and G, which are distinguished by being neutralized with a type-specific antibody. According to the different serotypes of botulinum toxin, there are differences in the animal species affected thereby, and the severity and duration of paralysis caused thereby. Botulinum toxin apparently binds to cholinergic motor neurons with high affinity, relocates to a neuron, and blocks the presynaptic release of acetylcholine.

[0006] Botulinum toxin has been used in a clinical setting for treating neuromuscular disorders characterized by hyperactive skeletal muscle. Botulinum toxin type A is approved by the U.S. Food and Drug Administration (FDA) for essential blepharospasm, strabismus and hemifacial spasm in patients over age 12, and also approved for the treatment of cervical dystonia, glabellar (facial) wrinkles and hyperhidrosis. The FDA also approved botulinum toxin type B for the treatment of cervical dystonia, glabellar (facial) wrinkles.

[0007] Botulinum toxin type A is known to be soluble in a dilute aqueous solution with pH 4 to 6.8. A stabilizing non-toxic protein is separated from a neurotoxin at pH of approximately 7 or more, resulting in a gradual loss of toxicity, especially as the pH and temperature rise. As is common with enzymes, the biological activity of botulinum toxin (which is an intracellular peptidase) is at least partially dependent on the three-dimensional morphology thereof. Dilution to a solution containing of milligrams to nanograms of toxin per mL has considerable difficulty, for example, the tendency of reducing an amount of available toxin by the toxin adhering to a surface. In addition, a toxin-containing pharmaceutical composition is sometimes used months or years after preparation, and in this case, the toxin may be easily oxidized or decomposed into small fragments due to the nature of a protein. Therefore, it is necessary to stabilize the toxin with a stabilizer.

[0008] Conventionally, to solve this problem, albumin, sucrose, trehalose and/or gelatin are mainly used as a stabilizer in the pharmaceutical process of a botulinum toxin protein.

[0009] For example, as described below, for a botulinum toxin-containing pharmaceutical composition, albumin is used as a stabilizer.

[0010] A commercially available botulinum toxin-containing pharmaceutical composition is commercialized by Allergan, Inc (Irvine, CA) under the trade name BOTOX® (botulinum toxin type A, purified neurotoxin complex). 100 units/vial of BOTOX® consists of approximately 5 ng of the purified botulinum toxin type A complex, 0.5 mg human serum albumin, and 0.9 mg sodium chloride, and is in a vacuum-dried form, and prepared to be restored with sterile physiological saline without a preservative (injected with 0.9% sodium chloride). Other commercially available botulinum toxin-containing pharmaceutical compositions may include Dysport® (*Clostridium botulinum* type A toxin-hemagglutinin complex having lactose and human serum albumin among a botulinum toxin pharmaceutical composition, commercially available from Ipsen Limited, Berkshire, UK, a powder to be restored with 0.9% sodium chloride before use), and MyoBloc™ (an injectable solution containing botulinum toxin type B, human serum albumin, sodium succinate and sodium chloride at approximately pH 5.6, commercially available from Solstice Neurosciences, San Diego, CA). A neurotoxin component (150 kDa toxin molecule) and a botulinum toxin complex (300 kDa to 900 kDa) may be obtained from, for example, List Biological Laboratories, Inc (Campbell, CA); the Centre for Applied Microbiology and Research (Porton Down, UK); and Wako (Osaka, Japan), and also from Sigma Chemicals (Saint Louis, MI).

[0011] As described above, the reason why albumin is mainly used is that albumin may not only stabilize a protein

active ingredient in a pharmaceutical composition, but may also have the advantage of negligible immunogenicity when injected into human patients. However, blood products such as albumin may pose a potential risk of infecting a patient with a blood-derived pathogen or infectious microorganism, and particularly, the mediation of diseases such as Creutzfeldt-Jacob disease delivered by viral infection or a viral protein may not be completely eliminated, and there may also be a risk of infecting a patient with a so far unknown pathogen. Therefore, when the above-described albumin is used as a stabilizer, selection of a donor or donation site is performed in a preparation process and the removal and/or inactivation of an infectious material should be performed to reduce the risk of spread of the infectious material.

[0012] In addition, gelatin is sometimes used. However, since it is also a protein obtained from an animal, it may cause a disease like albumin, and therefore may not be recommended for use in a pharmaceutical process.

[0013] As technology for using a stabilizer which is not derived from an animal source in a pharmaceutical process for a botulinum toxin protein, a method of utilizing a pharmaceutical preparation of recombinant albumin (rSA) produced in yeasts is disclosed in Korean Registered Patent No. 10-0799400. However, since a novel antigenic structure, neopeptide, is generated in the production and isolation and recovery of recombinant albumin (rSA), the possibility of inducing an immune response in a recipient of the drug may not be completely eliminated.

[0014] In addition, in Korean Registered Patent No. 10-0665469, a pharmaceutical composition containing botulinum toxin, a polysaccharide (including hydroxyethyl starch), and lysine, glycine, histidine or arginine as an amino acid is disclosed. However, the pharmaceutical composition of the present invention is a composition for a freeze-dried formulation, and its storage condition is limited to freezing or refrigeration. The freeze-dried botulinum toxin needs a process of melting or diluting a frozen formulation immediately before use, and in this process, an error may be generated. Moreover, the freeze-dried botulinum toxin is inconvenient in use, and has a problem of impossible development in a prefilled syringe type.

[0015] Regarding a composition for stabilizing botulinum toxin, in U.S. Unexamined Patent Application Publication No. 2007-0134199, a composition containing a non-ionic surfactant containing polysorbate, and glutamine and glutamic acid or asparagine and aspartic acid as amino acids is disclosed. When botulinum toxin is diluted in the liquid composition of the present invention and stored under a refrigeration condition of 4 °C, it is stabilized over 8 months, but when the botulinum toxin is stored at room temperature, for example, 37 °C, its activity is reduced within one month, so that there is a limit to stabilization of a pharmaceutical liquid composition containing botulinum toxin at room temperature.

[Disclosure]

[Technical Problem]

[0016] The present invention is directed to providing a stabilizing liquid composition which is safe for humans since it is not derived from an animal source, and improves the stability of a botulinum toxin solution to maintain the activity of botulinum toxin at room temperature, and a botulinum toxin solution with improved stability.

[0017] However, technical problems to be solved in the present invention are not limited to the above-described problems, and other problems which are not described herein will be fully understood by those of ordinary skill in the art from the following descriptions.

[Technical Solution]

[0018] To attain the above-described purposes,

the present invention provides a liquid composition for stabilizing botulinum toxin, which includes polysorbate 80 and serine as active ingredients.

[0019] In one embodiment of the present invention, in the composition, the composition ratio of polysorbate 80 and serine is 1 (mg/mL): 5 (mM) or more.

[0020] In another embodiment of the present invention, the composition further includes methionine.

[0021] In still another embodiment of the present invention, in the composition, the composition ratio of polysorbate 80, serine and methionine is 1 (mg/mL): 5 to 50 (mM) : 0.2 (mM).

[0022] In addition, the present invention provides a pharmaceutical composition in liquid formulation, which includes a liquid composition for stabilizing botulinum toxin; and botulinum toxin as active ingredients.

[0023] In one embodiment of the present invention, the concentration of polysorbate 80 is 0.001 mg or more per 40 units of botulinum toxin.

[0024] In one embodiment of the present invention, the concentration of serine is 5 mM or more per 40 units of botulinum toxin.

[0025] In one embodiment of the present invention, the concentration of methionine is less than 0.5 mM per 40 units of botulinum toxin.

[0026] In one embodiment of the present invention, the botulinum toxin is selected from the group consisting of bot-

ulimum type A, B, C, D, E, F, and G.

[0027] Preferably, the botulinum toxin is in a form that does not contain a complexing protein or a complex form that contains a complexing protein.

[0028] In addition, the present invention provides a method of stabilizing botulinum toxin, which includes mixing a liquid composition containing polysorbate 80 and serine with botulinum toxin.

[0029] In addition, the present invention provides a use of a liquid composition containing polysorbate 80 and serine for stabilizing botulinum toxin.

[0030] In addition, the present invention provides a use of polysorbate 80 and serine for producing a drug used to stabilize botulinum toxin.

[Advantageous Effects]

[0031] The present invention uses a stabilizer which is not derived from an animal source, and thus a patient administered a botulinum toxin pharmaceutical composition can secure safety from the potential risk of infection with a blood-derived pathogen or infectious microorganism. In addition, the present invention can ensure storage and distribution stability since the activity of botulinum toxin is maintained for a long time at room temperature. In addition, the present invention has improved convenience in preparation since there is no need for a freeze-drying process.

[Description of Drawings]

[0032]

FIG. 1 is a graph showing the change in mortality rate when a botulinum toxin solution is administered according to the change in concentration of polysorbate 80.

FIG. 2 is a graph showing the change in mortality rate when a botulinum toxin solution is administered according to the change in concentration of serine.

FIG. 3 is a graph showing the change in mortality rate when a botulinum toxin solution is administered according to the change in concentration of serine due to the addition of methionine.

[Modes of the Invention]

[0033] Hereinafter, to help in understanding the present invention, exemplary examples will be suggested. However, the following examples are merely provided to more easily understand the present invention, and not to limit the present invention.

[0034] The present invention relates to a liquid composition for stabilizing botulinum toxin, which includes polysorbate 80 and serine as active ingredients; and a pharmaceutical composition in liquid formulation, which includes the liquid composition for stabilizing botulinum toxin and botulinum toxin as active ingredients.

[0035] In addition, the present invention relates to a method of improving the stability of botulinum toxin using polysorbate 80 and serine.

[0036] The inventors conducted an experiment for ensuring a stabilizer which is safe since an animal-derived protein is not used, and has long-term stability at room temperature or even in storage in a refrigerator, as an alternative to a liquid composition for stabilizing botulinum toxin consisting of the combination of methionine and polysorbate 20. As a result, it was confirmed that the combination of serine and polysorbate 80 has an excellent effect of maintaining the activity of botulinum toxin at room temperature for a long time, and the present invention was completed.

[0037] In the present invention, the "stability or stabilization" means that the activity of botulinum toxin is maintained, and for example, the activity of botulinum toxin is maintained to be 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%, preferably, 50% or more, and most preferably, 100%, compared with that before the experiment or under specific conditions. For example, compared with the number of subjects into which botulinum toxin is injected, a value obtained by (the number of dead subjects among subjects into which botulinum toxin is injected/the number of subjects into which botulinum toxin is injected) x 100 is maintained to be 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%, preferably, 50% or more, and most preferably, 100%. The activity of botulinum toxin may be measured according to various methods known in the art, and for example, measured with reference to the lethality assay method described in Pearce L.B. et al 1994. Measurement of Botulinum Toxin Activity: Evaluation of the Lethality Assay. Toxicology and Applied Pharmacology' 128: 69-77'. According to an experimental example of the present invention, 0.1 mL (3 or 4 units/0.1 mL/mouse) of the prepared botulinum toxin liquid composition was intraperitoneally injected into five or ten 4-week-old ICR (Institute of Cancer Research, USA) female mice, and then observed for 72 hours to confirm a mortality rate. In addition, the condition for "stability or stabilization" may refer to storage or

distribution stability at room temperature, but the present invention is not limited thereto. According to a specific embodiment, the stability or stabilization condition may be a 35 to 45 °C/50 to 80% RH condition, and preferably, a 40 °C/70% RH condition.

[0038] The liquid composition for stabilizing botulinum toxin according to the present invention includes polysorbate 80 and serine as active ingredients.

[0039] In addition, the pharmaceutical composition in liquid formulation according to the present invention includes the liquid composition for stabilizing botulinum toxin and botulinum toxin as active ingredients. That is, the pharmaceutical composition in liquid formulation includes polysorbate 80 and serine; and botulinum toxin as active ingredients.

[0040] In the present invention, the "serine" is a compound represented by the chemical formula $\text{HO}_2\text{CCH}(\text{NH}_2)\text{CH}_2\text{OH}$, and includes a stereoisomer thereof. The "serine" may be obtained by various methods known in the art, which include a chemical synthesis method, a method of separating serine synthesized in an animal body, or a method of obtaining a commercially available compound, and for example, serine may be prepared by a method of removing 3-phosphoserine and a phosphoric acid group by an amino group transfer reaction with glutamic acid starting from oxidation of 3-phosphoglycerate formed from 3-phosphohydroxypyruvate and nicotinamide adenine dinucleotide (NADH), but the present invention is not limited thereto. In the present invention, a serine concentration included in the pharmaceutical composition in liquid formulation may be 5 mM or more per 40 units of botulinum toxin, preferably, 5 to 100 mM per 40 units of botulinum toxin, more preferably, 15 to 100 mM per 40 units of botulinum toxin, and most preferably, 15 to 50 mM per 40 units of botulinum toxin. At the concentration of less than 5 mM per 40 units of botulinum toxin, the stabilization of botulinum toxin caused by serine may be exhibited at lower than a predetermined level in long-term storage, and at the concentration of more than 100 mM per 40 units of botulinum toxin, a synergistic effect caused by excessive serine may be no longer exhibited, and may not be economical.

[0041] In the present invention, the "polysorbate 80" is a compound represented by the chemical formula $\text{C}_{64}\text{H}_{124}\text{O}_{26}$, is a non-ionic surfactant, and is soluble. The polysorbate 80 is called monooleic acid polyoxyethylene sorbitan, polyoxyethylene sorbitan monooleate, emazole 4130, Tween 80, or Tween 79, and used as a food or cosmetic additive for the purpose of, for example, a plasticizer, a gelling agent, a surfactant, a base, a sugar-coated preparation, a water-proofing agent, an anti-adhesive agent, an excipient, a dispersing agent, a disintegrant, a wetting agent, a stabilizer, a softening agent, a buffer, a solvent, a solubilizing agent, an emulsifying agent, an enteric coating agent, a coating agent, a bleaching agent, a suspending agent or a lubricant. The polysorbate 80 may be prepared by various methods known in the art, and may be isolated in nature or chemically synthesized. In the present invention, the concentration of polysorbate 80 included in the pharmaceutical composition in liquid formulation may be 0.001 mg or more per 40 units of botulinum toxin, preferably, 0.1 to 5 mg per 40 units of botulinum toxin, more preferably 0.1 to 2 mg per 40 units of botulinum toxin, and most preferably, 0.5 to 2 mg per 40 units of botulinum toxin. At less than 0.001 mg per 40 units of botulinum toxin, the stabilization of botulinum toxin by polysorbate 80 may be exhibited at less than a predetermined level in long-term storage, and at more than 5 mg per 40 units of botulinum toxin, a synergistic effect caused by excessive polysorbate 80 may be no longer exhibited, and may not be economical.

[0042] In the liquid composition for stabilizing botulinum toxin of the present invention, the composition ratio of polysorbate 80: serine per 20 units of botulinum toxin may be 1 (mg/mL): 5 (mM) or more, preferably, 1 (mg/mL): 5 to 50 (mM), and more preferably, 1 (mg/mL): 15 to 50 (mM). When the composition ratio of polysorbate 80 : serine is 1 (mg/mL): less than 5 (mM), the stabilization of botulinum toxin may be exhibited at less than a predetermined level in long-term storage.

[0043] In the present invention, the "botulinum toxin" may be randomly selected from the group consisting of botulinum type A, B, C, D, E, F and G, and preferably botulinum type A. The botulinum toxin may include both a form that does not contain a complexing protein and a complex form that contains a complexing protein. The molecular weight of a botulinum toxin protein derived from *Clostridium botulinum* type A, B, C, D, E, F or G, which does not contain a naturally-occurring complexing protein, is approximately 150 kDa. However, when a toxin protein is produced by *Clostridium botulinum*, a botulinum toxin protein is produced by forming various complexes with several hemagglutinin proteins that assist and protect the action of the botulinum toxin protein and non-hemagglutinin proteins. Botulinum toxin type A containing a naturally-occurring complexing protein is a complex having a molecular weight of approximately 900 kDa, 500 kDa or 300 kDa, botulinum toxin types B and C are complexes having a molecular weight of approximately 500 kDa, botulinum toxin type D is a complex having a molecular weight of approximately 300 kDa or 500 kDa, and botulinum toxin types E and F are complexes having a molecular weight of approximately 300 kDa. In the present invention, 1 unit of botulinum toxin may be defined as LD_{50} , in which a mortality rate caused by intraperitoneal injection into female Swiss Webster mice weighing 18 to 20 g is 50%.

[0044] As an active ingredient for the liquid composition for stabilizing botulinum toxin according to the present invention, methionine may be further included in addition to serine and polysorbate 80.

[0045] In the present invention, the concentration of methionine included in the pharmaceutical composition in liquid formulation may be less than 0.5 mM per 40 units of botulinum toxin, and more preferably, 0.2 to 0.4 mM per 40 units of botulinum toxin, but the present invention is not limited thereto.

[0046] In the liquid composition for stabilizing botulinum toxin of the present invention, the composition ratio of polysorbate 80 : serine : methionine per 20 units of botulinum toxin may be 1 (mg/mL) : 2.5 to 50 (mM) : 0.2 (mM), preferably 1 (mg/mL) : 5 to 50 (mM) : 0.2 (mM), more preferably 1 (mg/mL) : 7.5 to 30 (mM) : 0.2 (mM), and further more preferably 1 (mg/mL) : 7.5 to 25 (mM) : 0.2 (mM). When the composition ratio of polysorbate 80 : serine : methionine is 1 (mg/mL) : less than 2.5 or more than 50 (mM) : 0.2 (mM), the stabilization of botulinum toxin may be exhibited at less than a predetermined level in long-term storage.

[0047] According to the present invention, the liquid composition for stabilizing botulinum toxin and/or the pharmaceutical composition in liquid formulation including the same may include a pharmaceutically acceptable carrier in addition to the active ingredients. Here, the pharmaceutically acceptable carrier is conventionally used in preparation, and includes, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but the present invention is not limited thereto. In addition, the liquid composition for stabilizing botulinum toxin and/or pharmaceutical composition in liquid formulation of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifier, a suspending agent or a preservative, in addition to the above-described ingredients.

[0048] The pharmaceutical composition of the present invention may be orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or locally) administered by a desired method, and a dose may be suitably selected by those of ordinary skill in the art according to the condition and body weight of a patient, the severity of a disease, a dosage form, the route and duration of administration.

[0049] The composition according to the present invention is administered at a pharmaceutically effective amount. In the present invention, the "pharmaceutically effective amount" used herein refers to an amount sufficient for treating a disease at a reasonable benefit/risk ratio applicable for medical treatment, and an effective dosage may be determined by parameters including the type of a patient's disease, severity, drug activity, sensitivity to a drug, administration time, an administration route and an excretion rate, the duration of treatment and drugs simultaneously used, and other parameters well known in the medical field.

[0050] The pharmaceutical composition of the present invention may be administered separately or in combination with other therapeutic agents, and may be sequentially or simultaneously administered with a conventional therapeutic agent, or administered in a single or multiple dose(s). In consideration of all of the above-mentioned parameters, it is important to achieve the maximum effect with the minimum dose without a side effect, and such a dose may be easily determined by one of ordinary skill in the art. The co-administered preparation is not limited, and for example, the second composition may be an aminoglycoside-based antibiotic or a drug that interferes with muscle and neurotransmission (tubocurarine-based muscle relaxant).

[0051] In addition, the present invention provides a method of stabilizing botulinum toxin, which includes mixing a liquid composition including polysorbate 80 and serine with botulinum toxin.

[0052] In addition, the present invention provides a use of a liquid composition including polysorbate 80 and serine for stabilizing botulinum toxin and a use of polysorbate 80 and serine for producing a drug used to stabilize botulinum toxin.

[0053] In addition, the "subject" used herein refers to a target in need of administration of botulinum toxin, and more specifically, and includes a mammal such as a human or a non-human primate, a mouse, a rat, a dog, a cat, a horse, or a cow.

[0054] The "administration" used herein refers to the provision of the liquid composition including polysorbate 80 and serine; and botulinum toxin to a subject by a suitable method.

[0055] The liquid composition for stabilizing botulinum toxin according to the present invention is prepared by mixing serine and polysorbate 80.

[0056] In addition, the pharmaceutical composition in liquid formulation according to the present invention is prepared by preparing a liquid composition for stabilizing botulinum toxin by mixing serine and polysorbate 80; and mixing the liquid composition for stabilizing botulinum toxin and botulinum toxin.

[0057] As needed, in addition to the above-described steps, one or more steps may be further included, and the sequence is irrelevant. For example, the liquid composition for stabilizing botulinum toxin may include additionally mixing methionine in the step of mixing serine and polysorbate 80.

<Example>

1. Preparation of liquid composition containing botulinum toxin

[0058] A liquid composition containing botulinum toxin was prepared by diluting a botulinum toxin solution using a liquid composition for stabilizing botulinum toxin adjusted to a proper concentration and finally adjusting the concentration of the botulinum toxin solution to a proper concentration.

<Experimental Examples>

1. Test for selecting liquid composition for stabilizing botulinum toxin

[0059] To select a stabilizer of *Clostridium botulinum* toxin type A, an experiment for selecting the composition of a liquid composition for stabilizing botulinum toxin was performed using various stabilizers.

[0060] Using a liquid composition for stabilizing botulinum toxin having the composition as shown in Table 1 below, a botulinum toxin solution was prepared to have a concentration of 300 Unit/mL.

[0061] Like the patented Innotox formulation, a control was prepared by dissolving 20 mM methionine and 2 mg/mL polysorbate 20 in 10% saline. In addition, experimental groups (Examples 1 to 7) were prepared by dissolving each a 20 mM stabilizer in normal saline and dissolving 2 mg/mL of polysorbate 80 in 10% saline.

[0062] The prepared botulinum toxin solution was stored in a stability chamber under conditions including 40 °C/70% RH, and sampled at regular intervals. 9 mL of an injectable solution (normal saline) was added to 1 mL of the sampled botulinum toxin solution to dilute the solution 10-fold, and the diluted sample was intraperitoneally injected into five 4-week-old ICR (Institute of Cancer Research, USA) female mice at 3 units/0.1 mL (1 unit = LD₅₀). While observing for 72 hours after the intraperitoneal injection, the number of dead mice and the mortality rate corresponding thereto were assessed.

[0063] As a result, as shown in Table 1, other than Examples 1 and 4, and Control, a dramatic decrease in stability was confirmed. That is, the activity of botulinum toxin was maintained for a long time only in Examples 1 and 4 and Control.

[0064] From the above result, it can be seen that the combination of serine and polysorbate 80 is a stabilizer that can replace the combination of methionine and polysorbate 80.

[Table 1]

Classification	Liquid composition for stabilizing botulinum toxin		Mortality rate (%)			Stability
	Stabilizer (20 mM)	Polysorbate (2 mg/mL)	0 week	1 st week	2 nd week	
Control	Methionine	Tween 20	100%	100%	100%	○
Example 1	Methionine	Tween 80	100%	100%	100%	○
Example 2	Glycine	Tween 80	100%	100%	0%	X
Example 3	Cysteine	Tween 80	100%	0%	0%	X
Example 4	Serine	Tween 80	100%	100%	100%	○
Example 5	Zn (50 mM)	Tween 80	100%	40%	0%	X
Example 6	Leucine	Tween 80	80%	60%	0%	X
Example 7	Vitamin C	Tween 80	80%	0%	0%	X

[0065] However, the stability experiment was performed on live mice, and due to its characteristic, even when the stability experiment was conducted with a botulinum toxin liquid composition having the same composition, different results may be obtained depending on the condition of a mouse.

2. Test for stability of botulinum toxin according to change in concentration of polysorbate 80

[0066] As the composition of the liquid composition for stabilizing botulinum toxin, the combination of serine and polysorbate 80 was selected, and an experiment for the stability of botulinum toxin according to the change in concentration of polysorbate 80 was performed.

[0067] Using a liquid composition for stabilizing botulinum toxin having the composition as described in Table 2 below, a botulinum toxin solution was prepared to have a concentration of 40 units/mL. An experimental group was prepared by dissolving 5 mM serine and 0.001 to 2 mg/mL of polysorbate 80 in 10% normal saline. A specific experimental method was carried out as described in Experimental Example 1. However, this method used 10 mice, and a concentration for intraperitoneal injection was 4 units/0.1 mL.

[0068] The result of an experiment for the stability of botulinum toxin according to the change in concentration of polysorbate 80 is shown in Table 2 and FIG. 1. When the concentration of polysorbate 80 is 0.1 mg/mL or more, a certain degree or more of stability was shown at every concentration. When the concentration of polysorbate 80 is 0.1 mg/mL, 0.5 mg/mL and 2 mg/mL, a mortality rate was 50% or more until the 6th week, and when the concentration of polysorbate

80 was 0.5 mg/mL or 2 mg/mL, a mortality rate was 10% until the 10th week.

[Table 2]

Botulinum toxin solution			Mortality rate (%)							
Liquid composition for stabilizing botulinum toxin		Toxin (U/mL)	0 week	1 st week	2 nd week	4 th week	6 th week	8 th week	10 th week	12 th week
Polysorbate 80 (mg/mL)	serine (mM)									
0.001	5	40	100%	0%	0%	0%	0%	0%	0%	0%
0.01			100%	100%	80%	60%	0%	0%	0%	0%
0.1			100%	100%	90%	90%	60%	30%	0%	0%
0.5			100%	90%	80%	70%	100%	40%	10%	0%
2			100%	70%	100%	70%	70%	40%	10%	0%

3. Test for stability of botulinum toxin according to change in concentration of serine

[0069] An experiment for the stability of botulinum toxin according to the change in concentration of serine was performed with the combination of serine and polysorbate 80 selected as the composition of a liquid composition for stabilizing botulinum toxin.

[0070] Using a liquid composition for stabilizing botulinum toxin having the composition as described in Table 3 below, a botulinum toxin solution was prepared to have a concentration of 40 Unit/mL. A control was prepared by dissolving 20 mM methionine and 2 mg/mL of polysorbate 20 in 10% saline like the patented Innotox formulation. An experimental group was prepared by dissolving 0.1 mg/mL of polysorbate 80 and 5 to 50 mM serine in 10% normal saline. A specific experimental method was carried out as described in Experimental Example 1. However, this method used 10 mice, and a concentration for intraperitoneal injection was 4 units/0.1 mL.

[0071] The result of an experiment for the stability of botulinum toxin according to the change in concentration of serine is shown in Table 3 and FIG. 2. When the concentration of serine is 5 mM, 15 mM or 50 mM, the mortality rate was 50% or more until the 6th week, showing that the activity of botulinum toxin is maintained. Particularly, when the concentration of serine is 50 mM, the mortality rate was 50% or more until the 12th week, showing that the stability of botulinum toxin is maintained for a long time compared with the combination of 20 mM methionine and 2 mg/mL of polysorbate 20.

[Table 3]

Liquid composition for stabilizing botulinum toxin		Mortality rate (%)							
Serine (mM)	Polysorbate 80 (mg/mL)	0 week	1 st week	2 nd week	4 th week	6 th week	8 th week	10 th week	12 th week
5	0.1	100%	90%	90%	100%	80%	20%	0%	0%
15		100%	90%	100%	100%	70%	40%	0%	20%
50		100%	80%	100%	80%	90%	70%	50%	50%
20mM methionine,2mg/mL polysorbate20		100%	90%	80%	100%	90%	90%	20%	20%

4. Test for stability of botulinum toxin according to addition of methionine

[0072] An experiment for the stability of botulinum toxin according to the addition of methionine was performed with the combination of serine and polysorbate 80 selected as the composition of a liquid composition for stabilizing botulinum toxin.

[0073] Using a liquid composition for stabilizing botulinum toxin having the composition as described in Table 4 below, a botulinum toxin solution was prepared to have a concentration of 40 units/mL. A control was prepared by dissolving 20 mM methionine and 2 mg/mL of polysorbate 20 in 10% saline like the patented Innotox formulation. An experimental

EP 3 888 633 A1

group was prepared by dissolving 2 mg/mL of polysorbate 80, 5 to 50 mM serine and 0.4 mM methionine in 10% normal saline. A specific experimental method was carried out as described in Experimental Example 1. However, this method used 10 mice, and a concentration for intraperitoneal injection was 4 units/0.1 mL.

5

10

15

20

25

30

35

40

45

50

55

[Table 4]

Botulinum toxin solution				Mortality rate (%)							Stability		
Liquid composition for stabilizing botulinum toxin				Toxin (U/mL)	0 week	2 nd week	4 th week	6 th week	8 th week	10 th week		12 th week	
Methionine (mM)	Serine (mM)	Polysorbate 80 (mg/mL)											
0.4	5	2											
0.4	15	2											
0.4	50	2											
Methionine 20mM, Polysorbate 20 2mg/mL				40	100	100	80	80	90	80	60	60	△

[0074] As a result, as shown in Table 4 and FIG. 3, it can be seen that the stability of the botulinum toxin solution was improved by the combination of methionine, serine and polysorbate 80 in all formulations, compared with a control.

[0075] It should be understood by those of ordinary skill in the art that the above description of the present invention is exemplary, and the exemplary embodiments disclosed herein can be easily modified into other specific forms without departing from the technical spirit or essential features of the present invention. Therefore, the exemplary embodiments described above should be interpreted as illustrative and not limited in any aspect.

[Industrial Applicability]

[0076] Polysorbate 80 and serine according to the present invention are expected to be effectively used in a composition for improving the stability and ease of administration of liquid botulinum toxin.

Claims

1. A liquid composition for stabilizing botulinum toxin, comprising polysorbate 80 and serine as active ingredients.
2. The composition of claim 1, wherein the composition ratio of polysorbate 80 : serine is 1 (mg/mL): 5 (mM) or more.
3. The composition of claim 1, further comprising methionine.
4. The composition of claim 3, wherein the composition ratio of polysorbate 80 : serine: methionine is 1 (mg/mL): 5 to 50 (mM) : 0.2 (mM).
5. A pharmaceutical composition in liquid formulation, comprising the liquid composition for stabilizing botulinum toxin of any one of claims 1 to 4; and botulinum toxin as active ingredients.
6. The pharmaceutical composition of claim 5, wherein the concentration of polysorbate 80 is 0.001 mg or more per 40 units of the botulinum toxin.
7. The pharmaceutical composition of claim 5, wherein the concentration of serine is 5 mM or more per 40 units of the botulinum toxin.
8. The pharmaceutical composition of claim 5, wherein the concentration of methionine is less than 0.5 mM per 40 units of the botulinum toxin.
9. The pharmaceutical composition of claim 5, wherein the botulinum toxin is selected from the group consisting of botulinum type A, B, C, D, E, F and G.
10. The pharmaceutical composition of claim 5, wherein the botulinum toxin is a form that does not contain a complexing protein or a complex form that contains a complexing protein.
11. A method for stabilizing botulinum toxin, comprising:
mixing a liquid composition comprising polysorbate 80 and serine with botulinum toxin.
12. A use of a liquid composition comprising polysorbate 80 and serine for stabilizing botulinum toxin.

FIG.1




FIG.2





FIG.3



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2019/016669

A. CLASSIFICATION OF SUBJECT MATTER

A61K 9/08(2006.01)i, A61K 47/26(2006.01)i, A61K 47/18(2006.01)i, A61K 47/20(2006.01)i, A61K 47/64(2017.01)i, A61K 38/48(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 9/08; A61K 35/74; A61K 38/16; A61K 38/17; A61K 38/48; A61K 47/10; A61K 47/12; A61K 47/18; A61K 47/26; A61K 47/42; A61K 47/20; A61K 47/64

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models: IPC as above
Japanese utility models and applications for utility models: IPC as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS (KIPO internal) & Key words: polysorbate 80, serine, botulinum, methionine, liquid

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KR 10-2016-0103551 A (ALLERGAN, INC.) 01 September 2016 See paragraphs [0002], [0011], [0030], [0038]; claims 1, 5, 6, 8, 9, 12.	1-12
A	KR 10-2009-0005963 A (MEDYTOX INC.) 14 January 2009 See claims 1, 8.	1-12
A	KR 10-2012-0112248 A (MEDYTOX INC.) 11 October 2012 See claims 1, 2, 4.	1-12
A	KR 10-2018-0023871 A (ABBIO CO., LTD. et al.) 07 March 2018 See the entire document.	1-12
A	US 2015-0071879 A1 (ARECOR LTD.) 12 March 2015 See the entire document.	1-12

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 MARCH 2020 (24.03.2020)

Date of mailing of the international search report

24 MARCH 2020 (24.03.2020)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
Government Complex Daejeon Building 4, 189, Cheongsu-ro, Seo-gu,
Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

Telephone No.

INTERNATIONAL SEARCH REPORT
 Information on patent family members

International application No.

PCT/KR2019/016669

Patent document cited in search report	Publication date	Patent family member	Publication date
KR 10-2016-0103551 A	01/09/2016	AU 2006-299366 A1	12/04/2007
		AU 2006-299366 B2	12/01/2012
		AU 2009-339292 A1	07/07/2011
		AU 2009-339292 B2	21/01/2016
		BR P10613001 A2	14/12/2010
		BR P10613001 B1	17/09/2019
		CA 2602926 A1	12/04/2007
		CA 2602926 C	21/12/2010
		CA 2746425 A1	12/08/2010
		CA 2746425 C	03/05/2016
		CN 101175478 A	07/05/2008
		CN 102307571 A	04/01/2012
		CN 105833254 A	10/08/2016
		CY 1117727 T1	17/05/2017
		DK 2679217 T3	25/07/2016
		EP 1931306 A1	18/06/2008
		EP 1931306 B1	31/07/2013
		EP 2373294 A1	12/10/2011
		EP 2373294 B1	20/04/2016
		EP 2679217 A1	01/01/2014
		EP 2679217 B1	06/04/2016
		EP 3067049 A1	14/09/2016
		ES 2580010 T3	18/08/2016
		HK 1192710 A1	07/04/2017
		HU E027810 T2	28/11/2016
		JP 2009-511485 A	19/03/2009
		JP 2012-197320 A	18/10/2012
		JP 2012-512162 A	31/05/2012
		JP 2014-139229 A	31/07/2014
		JP 2015-178505 A	08/10/2015
		JP 2017-088611 A	25/05/2017
		JP 2017-186348 A	12/10/2017
		JP 2019-108381 A	04/07/2019
		JP 5140595 B2	06/02/2013
		JP 5758856 B2	05/08/2015
		JP 6235176 B2	22/11/2017
		JP 6424135 B2	14/11/2018
		KR 10-1314952 B1	04/10/2013
		KR 10-2008-0052510 A	11/06/2008
		KR 10-2011-0106346 A	28/09/2011
		MX 2007012062 A	04/12/2007
		NZ 562033 A	22/12/2011
		PL 2679217 T3	30/11/2016
		PT 2679217 T	15/07/2016
		RU 2011125601 A	20/01/2013
		RU 2535003 C2	10/12/2014
		SI 2679217 T1	31/08/2016
		US 2007-0082633 A1	12/04/2007
		US 2010-0279953 A1	04/11/2010

Form PCT/ISA/210 (patent family annex) (January 2015)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR2019/016669

Patent document cited in search report	Publication date	Patent family member	Publication date
		US 2012-0122802 A1	17/05/2012
		US 2012-0141619 A1	07/06/2012
		US 2012-0207787 A1	16/08/2012
		US 2014-0112908 A1	24/04/2014
		US 8137677 B2	20/03/2012
		US 8168206 B1	01/05/2012
		US 8642047 B2	04/02/2014
		WO 2007-041664 A1	12/04/2007
		WO 2007-044218 A2	19/04/2007
		WO 2007-044218 A3	08/11/2007
		WO 2010-090677 A1	12/08/2010
KR 10-2009-0005963 A	14/01/2009	BR P10813948 A2	28/06/2016
		BR P10813948 B1	06/08/2019
		CA 2690773 A1	15/01/2009
		CA 2690773 C	17/09/2013
		CN 101687046 A	31/03/2010
		CN 101687046 B	26/12/2012
		EP 2170400 A1	07/04/2010
		EP 2170400 B1	25/07/2012
		ES 2391798 T3	30/11/2012
		JP 2010-532784 A	14/10/2010
		JP 5259710 B2	07/08/2013
		RU 2009148286 A	27/06/2011
		RU 2440825 C2	27/01/2012
		US 10293034 B2	21/05/2019
		US 2010-0291136 A1	18/11/2010
		US 2014-0161783 A1	12/06/2014
		US 2016-0206710 A1	21/07/2016
		US 2019-0298813 A1	03/10/2019
		US 8617568 B2	31/12/2013
		US 9220780 B2	29/12/2015
		WO 2009-008595 A1	15/01/2009
KR 10-2012-0112248 A	11/10/2012	AU 2012-233845 A1	31/10/2013
		AU 2012-233845 B2	19/11/2015
		AU 2016-201040 A1	10/03/2016
		AU 2016-201040 B2	25/05/2017
		BR 112013025256 A2	07/02/2017
		CA 2831908 A1	04/10/2012
		CA 2831908 C	13/11/2018
		CN 103596580 A	19/02/2014
		CN 109925284 A	25/06/2019
		CO 6821888 A2	31/12/2013
		DK 2692350 T3	21/08/2017
		EP 2692350 A2	05/02/2014
		EP 2692350 B1	03/05/2017
		EP 3241547 A1	08/11/2017
		ES 2636680 T3	06/10/2017
		IL 228607 A	31/12/2013

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR2019/016669

Patent document cited in search report	Publication date	Patent family member	Publication date
		JP 2014-509644 A	21/04/2014
		JP 2016-020382 A	04/02/2016
		JP 2016-199599 A	01/12/2016
		JP 5826914 B2	02/12/2015
		JP 6005239 B2	12/10/2016
		JP 6173547 B2	02/08/2017
		KR 10-1395064 B1	19/05/2014
		MX 2013011119 A	27/02/2014
		MX 338436 B	18/04/2016
		MX 355771 B	30/04/2018
		PL 2692350 T3	31/10/2017
		RU 2013148119 A	27/05/2015
		RU 2574011 C2	27/01/2016
		RU 2640922 C1	12/01/2018
		SG 10201605324 A	30/08/2016
		SG 194039 A1	29/11/2013
		US 2014-0086900 A1	27/03/2014
		US 2015-0064166 A1	05/03/2015
		US 2016-0089442 A1	31/03/2016
		US 8920795 B2	30/12/2014
		US 9198958 B2	01/12/2015
		WO 2012-134240 A2	04/10/2012
		WO 2012-134240 A3	03/01/2013
		ZA 201308115 B	30/07/2014
KR 10-2018-0023871 A	07/03/2018	BR 112019003770 A2	21/05/2019
		CA 3033729 A1	01/03/2018
		CN 109640954 A	16/04/2019
		EP 3505155 A1	03/07/2019
		JP 2019-529530 A	17/10/2019
		KR 10-1919299 B1	16/11/2018
		KR 10-1997615 B1	08/07/2019
		KR 10-2018-0023872 A	07/03/2018
		KR 10-2018-0123459 A	16/11/2018
		US 2019-0201506 A1	04/07/2019
		WO 2018-038301 A1	01/03/2018
		WO 2018-038585 A1	01/03/2018
US 2015-0071879 A1	12/03/2015	CA 2674765 A1	17/07/2008
		CA 2674765 C	05/05/2015
		EP 2114456 A2	11/11/2009
		EP 2114456 B1	04/03/2015
		ES 2537963 T3	16/06/2015
		JP 2010-515713 A	13/05/2010
		JP 5541925 B2	09/07/2014
		US 2010-0028372 A1	04/02/2010
		US 2017-0202954 A1	20/07/2017
		WO 2008-084237 A2	17/07/2008
		WO 2008-084237 A3	30/10/2008

Form PCT/ISA/210 (patent family annex) (January 2015)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- KR 1020180151983 [0002]
- KR 1020190101723 [0002]
- KR 100799400 [0013]
- KR 100665469 [0014]
- US 20070134199 [0015]

Non-patent literature cited in the description

- **PEARCEL.B. et al.** Measurement of Botulinum Toxin Activity: Evaluation of the Lethality Assay. *Toxicology and Applied Pharmacology*, 1994, vol. 128, 69-77 [0037]